{"schema":"sb.node.v1","id":"sb:e/89328883ec81e9c289c8d8f7","kind":"entity","label":{"text":"zepbound","locale":"en"},"identity":{"anchor":"label:en:zepbound","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T21:52:38.794589+00:00","snapshot":"deploy 42fcb912508e16b96962a1bf0a5ae2df232e259a"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":45,"separatePublishers":23,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-03","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.244: about 76% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","fda_decisions"],"activeDays":22,"assertions":{"utterance":3,"acquisition":2,"regulatory-approval":2,"meeting-visit":2,"launch-release":1,"price-threshold":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/17c49facffcdcceb27271191","kind":"observation","label":"24/7 Wall St. · 2026-10-07 · Lilly’s Worst Entry Points Were Its Most Hyped Approvals Mounjaro and Zepbound","url":"https://247wallst.com/investing/2026/10/07/lillys-worst-entry-points-were-its-most-hyped-approvals-mounjaro-and-zepbound/"},{"id":"sb:o/0fc334316370238ac476df54","kind":"observation","label":"Medical Daily · 2026-10-03 · Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss","url":"https://www.medicaldaily.com/rhode-island-medicaid-glp1-weight-loss-coverage-ends-479465"},{"id":"sb:o/c974ea4c5084349b1a3fb6e4","kind":"observation","label":"Business Model Analyst · 2026-10-02 · Lilly’s New Obesity Combo Beat Zepbound With a Third of the Zepbound","url":"https://businessmodelanalyst.com/lilly-eloratzp-tirzepatide-dose-sparing-amylin/"},{"id":"sb:o/b57718540add577e780cf097","kind":"observation","label":"STAT News · 2026-10-01 · STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial","url":"https://www.statnews.com/2026/09/30/eli-lilly-zepbound-amylin-combination-drug-study/?utm_campaign=rss"},{"id":"sb:o/7238729f499957a26b02a9bd","kind":"observation","label":"Latest Science News -- ScienceDaily · 2026-09-27 · Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat","url":"https://www.sciencedaily.com/releases/2026/09/260925093210.htm"},{"id":"sb:o/5b1b1f6a23cee364bb8657dc","kind":"observation","label":"Fierce Pharma · 2026-10-07 · Noom puts a spooky voice to the haunting threat of weight regain for GLP-1 users in new spot","url":"https://www.fiercepharma.com/marketing/noom-puts-spooky-voice-haunting-threat-weight-regain-glp-1-users-new-spot"},{"id":"sb:o/acdd3327df1a1c659af6ea90","kind":"observation","label":"TIME · 2026-10-07 · Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?","url":"https://time.com/article/2026/10/07/compounding-pharmacies-weight-loss-drugs/"},{"id":"sb:o/c44b0d820735233534e97994","kind":"observation","label":"MIT Technology Review · 2026-10-06 · Weight-loss drugs show signs of slowing biological aging, say drugmakers","url":"https://www.technologyreview.com/2026/10/06/1145836/weight-loss-drugs-glp1-lilly-novo-aging-clocks/"},{"id":"sb:o/dbff6268f5a0929c18c765f4","kind":"observation","label":"Business Model Analyst · 2026-10-06 · Ozempic Diners Want Half Portions. They Won’t Get Half Prices.","url":"https://businessmodelanalyst.com/glp1-diners-half-portions-restaurant-pricing/"},{"id":"sb:o/059a957c9086586ba0b798f4","kind":"observation","label":"Medical Daily · 2026-10-05 · Postpartum GLP-1 Prescriptions Rose Nearly 24-Fold Among Privately Insured New Mothers, with Breastfeeding Safety Data Still Limited","url":"https://www.medicaldaily.com/postpartum-glp-1-prescriptions-new-mothers-jama-study-479505"}],"cursor":"c1.eyJpZCI6InNiOmUvODkzMjg4ODNlYzgxZTljMjg5YzhkOGY3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDIxOjUyOjM4Ljc5NDU4OSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":9,"byKind":{"co-mentioned":9},"items":[{"kind":"relation","label":"co-mentioned with glp-1 (44 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a5b22a202d1fdb613ee2dd47"},{"kind":"relation","label":"co-mentioned with eli lilly (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/bd43652248bcbe78a0b864d7"},{"kind":"relation","label":"co-mentioned with mounjaro (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1aad55717ea54b21c8655ef9"},{"kind":"relation","label":"co-mentioned with fda (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b3e9df7656cd61a7a3ee94ed"},{"kind":"relation","label":"co-mentioned with novo nordisk (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b101f67860e6abed8b8a4250"},{"kind":"relation","label":"co-mentioned with foundayo (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e19b7b85b945ca24862c1642"},{"kind":"relation","label":"co-mentioned with glp-1s (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ffef98eef7f4f1e6d6ce3e4a"},{"kind":"relation","label":"co-mentioned with denmark (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0858f21b7fef220fca6e3a52"},{"kind":"relation","label":"co-mentioned with nyse (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/859a2c43f1b138409ffc6378"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/89328883ec81e9c289c8d8f7","mcp":"traverse {\"id\":\"sb:e/89328883ec81e9c289c8d8f7\"}","page":"/entity/zepbound/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/89328883ec81e9c289c8d8f7\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/89328883ec81e9c289c8d8f7\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/89328883ec81e9c289c8d8f7\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/89328883ec81e9c289c8d8f7\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}